Targeting Myc-driven stress vulnerability in mutant KRAS colorectal cancer

Mutant KRAS is a key driver in colorectal cancer (CRC) and promotes Myc translation and Myc-dependent stress adaptation and proliferation. Here, we report that the combination of two FDA-approved drugs Bortezomib and Everolimus (RAD001) (BR) is highly efficacious against mutant KRAS CRC cells. Mecha...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruan, Hang, Leibowitz, Brian J., Peng, Yingpeng, Shen, Lin, Chen, Lujia, Kuang, Charlie, Schoen, Robert E., Lu, Xinghua, Zhang, Lin, Yu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934835/
https://www.ncbi.nlm.nih.gov/pubmed/35307764
http://dx.doi.org/10.1186/s43556-022-00070-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8934835/
https://www.ncbi.nlm.nih.gov/pubmed/35307764
http://dx.doi.org/10.1186/s43556-022-00070-7

Ejemplares similares